Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-09-05 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第三届监事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of Shanghai Medicilon Inc. It details the meeting date, attendance, and specific agenda items related to the company's 2021 restricted stock incentive plan, including approval of stock vesting, adjustments to grant quantities and prices, and cancellation of unvested shares. The document includes voting results and references compliance with relevant laws and regulations. There is no financial data or report content, only meeting resolutions and announcements. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or management bodies. The document is not an annual report, audit report, or earnings release, nor is it a regulatory filing or report publication announcement. Therefore, the classification is MANG with high confidence.
2022-09-05 Chinese
美迪西：独立董事关于第三届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters related to the company's third board meeting, specifically discussing the 2021 restricted stock incentive plan, adjustments to the grant quantity and price, and cancellation of some granted but unvested restricted stocks. It references compliance with various laws and regulations and confirms the legality and fairness of these corporate governance actions. The content focuses on board-level decisions and governance related to stock incentives rather than financial results, audit, or shareholder voting outcomes. It is not a full annual or interim report, nor an earnings release or capital update. The document is a governance-related opinion from independent directors on board matters, fitting the Board/Management Information (MANG) category.
2022-09-05 Chinese
美迪西：2021年限制性股票激励计划第一个归属期符合归属条件的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's 2021 restricted stock incentive plan, specifically about the first vesting period meeting the vesting conditions. It includes information about the stock grant, vesting conditions, board and supervisory opinions, legal opinions, and the number of shares and recipients involved. The document is not a full annual report or financial statement but a specific announcement about stock incentive plan vesting results. It is not a proxy solicitation or remuneration report but focuses on the stock incentive plan's vesting and related approvals. This fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement about stock incentive plan vesting conditions and approvals, not a full report or financial statement.
2022-09-05 Chinese
美迪西：监事会关于2021年限制性股票激励计划第一个归属期归属名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a statement from the Supervisory Board of Shanghai Medicilon Inc. regarding the verification opinion on the first vesting period list of the 2021 restricted stock incentive plan. It discusses compliance with relevant laws and regulations, confirms the legitimacy of the incentive recipients, and approves the vesting of restricted shares. The content focuses on stock incentive plan verification and approval rather than financial results, management changes, or shareholder voting results. It is not an annual or interim report, earnings release, or a regulatory filing about a report publication. The document is a formal announcement related to share-based incentive plans, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Share Issue/Capital Change or Director's Dealing, since it is about incentive plan verification and approval by the Supervisory Board.
2022-09-05 Chinese
美迪西：第三届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at a board meeting of Shanghai Medicilon Inc. It details decisions about the company's 2021 restricted stock incentive plan, including approval of stock vesting, adjustments to stock grant quantities and prices, and cancellation of unvested shares for certain employees. The document includes voting results and references to related announcements published on the Shanghai Stock Exchange website. It is not a full financial report, audit, or earnings release, nor is it a proxy solicitation or AGM materials. It is a formal announcement of board decisions related to stock incentive plans, which falls under Board/Management Information (MANG). The document length is short (1905 characters) and contains substantive content about board resolutions, not just a notice or link to a report, so it is not a Report Publication Announcement (RPA).
2022-09-05 Chinese
美迪西：关于举行2022年上海辖区上市公司集体接待日暨中报业绩说明会活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. about holding a 2022 mid-year performance explanation meeting (中报业绩说明会). It mentions the date, participants, and how investors can join and interact. The document is short (707 characters) and serves as a notice for an upcoming event rather than containing any financial data or detailed report. It does not contain actual financial statements or analysis, nor is it a transcript or presentation. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about an investor event and does not fit other specific categories.
2022-09-02 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.